Receptor tyrosine kinases in the nucleus: Nuclear functions and therapeutic implications in cancers

Cancer Drug Discovery and Development

Volumn 88, Issue , 2014, Pages 189-229

  Huo, Longfei ^a   Hsu, Jennifer L ^a,b,c   Hung, Mien Chie ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

Author keywords

c Met; DNA repair; Drug resistance; EGFR; FGFR; Gene transcription; IGF1R; rRNA biogenesis; Tyrosine kinase inhibitor; VEGFR

Indexed keywords

BETA ACTIN; CETUXIMAB; CISPLATIN; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EZRIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GLUCOSE REGULATED PROTEIN 78; MYC PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; RIBOSOME RNA; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR PAX5; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CALCIUM SIGNALING; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL FUNCTION; CELL NUCLEUS; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; GENE EXPRESSION; HUMAN; MOLECULAR GENETICS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEAR TRANSLOCATION; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; RNA SYNTHESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

EID: 85091806140     PISSN: 21969906     EISSN: 21969914     Source Type: Book Series    
DOI: 10.1007/978-1-4614-8039-6_8     Document Type: Article

References (256)

1. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117-1134.
2. Hubbard SR, Miller WT (2007) Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19(2):117-123.
3. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4(5):361-370.
4. Avraham R, Yarden Y (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12(2):104-117.
5. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2):177-184.
6. Gordus A, Krall JA, Beyer EM, Kaushansky A, Wolf-Yadlin A, Sevecka M et al (2009) Linear combinations of docking affinities explain quantitative differences in RTK signaling. Mol Syst Biol 5:235.
7. Casaletto JB, McClatchey AI (2012) Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 12(6):387-400.
8. Wang YN, Hung MC (2012) Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci 2(1):13.
9. Wang YN, Yamaguchi H, Hsu JM, Hung MC (2010) Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 29(28):3997-4006.
10. Carpenter G, Liao HJ (2009) Trafficking of receptor tyrosine kinases to the nucleus. Exp Cell Res 315(9):1556-1566.
11. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC (2005) Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65(1):338-348.
12. Hadzisejdic I, Mustac E, Jonjic N, Petkovic M, Grahovac B (2010) Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis. Mod Pathol 23(3):392-403.
13. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R et al (2005) Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11(16):5856-5862.
14. Hoshino M, Fukui H, Ono Y, Sekikawa A, Ichikawa K, Tomita S et al (2007) Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology 74(1):15-21.
15. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL et al (2009) Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 48(7):610-617.
16. Li CF, Fang FM, Wang JM, Tzeng CC, Tai HC, Wei YC et al (2012) EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. Ann Surg Oncol 19(2):443-454.
17. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM (2006) The role of HER1- HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12(1):123-130.
18. Dekanic A, Dintinjan RD, Budisavljevic I, Pecanic S, Butorac MZ, Jonjic N (2011) Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol 6:108.
19. Dillon MF, Stafford AT, Kelly G, Redmond AM, McIlroy M, Crotty TB et al (2008) Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer 15(3):745-753.
20. Schillaci R, Guzman P, Cayrol F, Beguelin W, Diaz Flaque MC, Proietti CJ et al (2012) Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer 12:74.
21. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT et al (2007) Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-684.
22. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, Begin LR et al (2006) Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12(9): 2730-2737.
23. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Filali-Mouhim A, Begin LR et al (2007) Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int 100(2):303-309.
24. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P et al (2005) Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65(4):1384-1393.
25. Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JM (2006) HER4 In breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4. Breast Cancer Res 8(2):R19.
26. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K (2008) Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 13(2):259-268.
27. Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD et al (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70(16):6412-6419.
28. Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I et al (2012) Insulinlike growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 48:3027-3035.
29. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II et al (2008) Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 14(19):6014-6022.
30. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y et al (2012) Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol 105(8):773-779.
31. Rotterud R, Fossa SD, Nesland JM (2007) Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. Histol Histopathol 22(4):349-363.
32. Maeng YH, Eun SY, Huh JS (2010) Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder. Korean J Urol 51(2):94-100.
33. Farkkila A, Pihlajoki M, Tauriala H, Butzow R, Leminen A, Unkila-Kallio L et al (2011) Serum vascular endothelial growth factor a (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro. J Clin Endocrinol Metab 96(12):E1973-E1981.
34. Zhang Y, Pillai G, Gatter K, Blazquez C, Turley H, Pezzella F et al (2005) Expression and cellular localization of vascular endothelial growth factor a and its receptors in acute and chronic leukemias: an immunohistochemical study. Hum Pathol 36(7):797-805.
35. Carrillo de Santa Pau E, Arias FC, Caso Pelaez E, Munoz Molina GM, Sanchez Hernandez I, Muguruza Trueba I et al (2009) Prognostic significance of the expression of vascular endothelial growth factors a, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 115(8):1701-1712.
36. Pozner-Moulis S, Cregger M, Camp RL, Rimm DL (2007) Antibody validation by quantitative analysis of protein expression using expression of met in breast cancer as a model. Lab Invest 87(3):251-260.
37. Brusevold IJ, Soland TM, Khuu C, Christoffersen T, Bryne M (2010) Nuclear and cytoplasmic expression of met in oral squamous cell carcinoma and in an organotypic oral cancer model. Eur J Oral Sci 118(4):342-349.
38. Rakowicz-Szulczynska EM, Herlyn M, Koprowski H (1988) Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. Cancer Res 48(24 Pt 1):7200-7206.
39. Rakowicz-Szulczynska EM, Koprowski H (1986) Identification of NGF receptor in chromatin of melanoma cells using monoclonal antibody to cell surface NGF receptor. Biochem Biophys Res Commun 140(1):174-180.
40. Rakowicz-Szulczynska EM, Linnenbach AJ, Koprowski H (1989) Intracellular receptor binding and nuclear transport of nerve growth factor in intact cells and a cell-free system. Mol Carcinog 2(1):47-58.
41. Rakowicz-Szulczynska EM, Otwiaska D, Rodeck U, Koprowski H (1989) Epidermal growth factor (EGF) and monoclonal antibody to cell surface EGF receptor bind to the same chromatin receptor. Arch Biochem Biophys 268(2):456-464.
42. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H (1986) Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci USA 83(11):3728-3732.
43. Savion N, Vlodavsky I, Gospodarowicz D (1981) Nuclear accumulation of epidermal growth factor in cultured bovine corneal endothelial and granulosa cells. J Biol Chem 256(3):1149-1154.
44. Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM et al (1991) Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 13(1):15-20.
45. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY et al (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3(9):802-808.
46. Cao H, Lei ZM, Bian L, Rao CV (1995) Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology 136(7):3163-3172.
47. Xie Y, Hung MC (1994) Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 203(3):1589-1598.
48. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z et al (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6(3):251-261.
49. Kim J, Jahng WJ, Di Vizio D, Lee JS, Jhaveri R, Rubin MA et al (2007) The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Res 67(19):9229-9237.
50. Tao Y, Song X, Deng X, Xie D, Lee LM, Liu Y et al (2005) Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by epstein-barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res 303(2):240-251.
51. Bitler BG, Goverdhan A, Schroeder JA (2010) MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 123(Pt 10):1716-1723.
52. Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J et al (2009) Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 139(3):610-622.
53. Huo L, Wang YN, Xia W, Hsu SC, Lai CC, Li LY et al (2010) RNA helicase a is a DNAbinding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Acad Sci USA 107(37):16125-16130.
54. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y et al (2005) Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7(6):575-589.
55. Lo HW, Cao X, Zhu H, Ali-Osman F (2010) Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 8(2):232-245.
56. Han W, Carpenter RL, Cao X, Lo HW (2012) STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. Mol Carcinog 1-11; doi: 10.1002/mc.21936.
57. Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q, Turkson J (2011) A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One 6(5):e19605.
58. Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y, Hung MC (2006) Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 45(1):10-17.
59. Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML et al (2008) Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating aurora-a gene expression. Nucleic Acids Res 36(13):4337-4351.
60. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D et al (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121(12):4712-4721.
61. Gu Y, Zhang S, Wu Q, Xu S, Cui Y, Yang Z et al (2010) Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer. J Exp Clin Cancer Res 29:6.
62. Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL et al (2011) Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancerresistant protein expression in gefitinib-resistant cells. J Biol Chem 286(23):20558-20568.
63. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J et al (2009) Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 4(6):e5933.
64. Piccione EC, Lieu TJ, Gentile CF, Williams TR, Connolly AJ, Godwin AK et al (2012) A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors. Oncogene 31(24):2953-2967.
65. Beguelin W, Diaz Flaque MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M et al (2010) Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol 30(23):5456-5472.
66. Li X, Kuang J, Shen Y, Majer MM, Nelson CC, Parsawar K et al (2012) The atypical histone MacroH2A1.2 Interacts with HER-2 protein in cancer cells. J Biol Chem 287(27): 23171-23183.
67. Adilakshmi T, Ness-Myers J, Madrid-Aliste C, Fiser A, Tapinos N (2011) A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination. J Neurosci 31(13):5106-5119.
68. Andrique L, Fauvin D, El Maassarani M, Colasson H, Vannier B, Seite P (2012) ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF. Cell Signal 24(5):1074-1085.
69. Jones FE (2008) HER4 Intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 13(2):247-258.
70. Carpenter G (2003) Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 15(2):143-148.
71. Komuro A, Nagai M, Navin NE, Sudol M (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278(35):33334-33341.
72. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L et al (2006) Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 66(16):7991-7998.
73. Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA et al (2010) The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer 9:150.
74. Paatero I, Jokilammi A, Heikkinen PT, Iljin K, Kallioniemi OP, Jones FE et al (2012) Interaction with ErbB4 promotes hypoxia-inducible factor-1alpha signaling. J Biol Chem 287(13):9659-9671.
75. Linggi B, Carpenter G (2006) ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. J Biol Chem 281(35):25373-25380.
76. Arasada RR, Carpenter G (2005) Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment. J Biol Chem 280(35):30783-30787.
77. Long W, Wagner KU, Lloyd KC, Binart N, Shillingford JM, Hennighausen L et al (2003) Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 130(21):5257-5268.
78. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L et al (2004) The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 167(3):469-478.
79. Zscheppang K, Dork T, Schmiedl A, Jones FE, Dammann CE (2011) Neuregulin receptor ErbB4 functions as a transcriptional cofactor for the expression of surfactant protein B in the fetal lung. Am J Respir Cell Mol Biol 45(4):761-767.
80. Allison JG, Das PM, Ma J, Inglis FM, Jones FE (2011) The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons. Neurosci Res 70(2):155-163.
81. Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G (2006) Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 127(1):185-197.
82. Stachowiak MK, Maher PA, Joy A, Mordechai E, Stachowiak EK (1996) Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells. Mol Biol Cell 7(8):1299-1317.
83. Somanathan S, Stachowiak EK, Siegel AJ, Stachowiak MK, Berezney R (2003) Nuclear matrix bound fibroblast growth factor receptor is associated with splicing factor rich and transcriptionally active nuclear speckles. J Cell Biochem 90(4):856-869.
84. Peng H, Moffett J, Myers J, Fang X, Stachowiak EK, Maher P et al (2001) Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell 12(2):449-462.
85. Reilly JF, Maher PA (2001) Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J Cell Biol 152(6):1307-1312.
86. Stachowiak EK, Fang X, Myers J, Dunham S, Stachowiak MK (2003) CAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1). J Neurochem 84(6):1296-1312.
87. Fang X, Stachowiak EK, Dunham-Ems SM, Klejbor I, Stachowiak MK (2005) Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation. J Biol Chem 280(31):28451-28462.
88. Baron O, Forthmann B, Lee YW, Terranova C, Ratzka A, Stachowiak EK et al (2012) Cooperation of nuclear fibroblast growth factor receptor 1 and Nurr1 offers new interactive mechanism in postmitotic development of mesencephalic dopaminergic neurons. J Biol Chem 287(24):19827-19840.
89. Lee YW, Terranova C, Birkaya B, Narla S, Kehoe D, Parikh A et al (2012) A novel nuclear FGF receptor-1 partnership with retinoid and Nur receptors during developmental gene programming of embryonic stem cells. J Cell Biochem 113(9):2920-2936.
90. Chioni AM, Grose R (2012) FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol 197(6):801-817.
91. Cerliani JP, Guillardoy T, Giulianelli S, Vaque JP, Gutkind JS, Vanzulli SI et al (2011) Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res 71(10):3720-3731.
92. Radulescu RT (1995) Insulin receptor alpha-subunit: a putative gene regulatory molecule. Med Hypotheses 45(2):107-111.
93. Radulescu RT (1995) From insulin, retinoblastoma protein and the insulin receptor to a new model on growth factor specificity: the nucleocrine pathway. J Endocrinol 146(3):365-368.
94. Gletsu N, Dixon W, Clandinin MT (1999) Insulin receptor at the mouse hepatocyte nucleus after a glucose meal induces dephosphorylation of a 30-kDa transcription factor and a concomitant increase in malic enzyme gene expression. J Nutr 129(12):2154-2161.
95. Nelson JD, LeBoeuf RC, Bomsztyk K (2011) Direct recruitment of insulin receptor and ERK signaling cascade to insulin-inducible gene loci. Diabetes 60(1):127-137.
96. Sarfstein R, Pasmanik-Chor M, Yeheskel A, Edry L, Shomron N, Warman N et al (2012) Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem 287(4):2766-2776.
97. Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J et al (2010) SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 3(108):ra10.
98. Warsito D, Sjostrom S, Andersson S, Larsson O, Sehat B (2012) Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF. EMBO Rep 13(3):244-250.
99. Wu YC, Zhu M, Robertson DM (2012) Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells. PLoS One 7(8):e42483.
100. Zscheppang K, Korenbaum E, Bueter W, Ramadurai SM, Nielsen HC, Dammann CE (2006) ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatr Pulmonol 41(12):1205-1212.
101. Baumann Kubetzko FB, Di Paolo C, Maag C, Meier R, Schafer BW, Betts DR et al (2004) The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 25(10):1839-1846.
102. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S et al (2009) PAX5 Is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 89(3):301-314.
103. Matteucci E, Bendinelli P, Desiderio MA (2009) Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 30(6):937-945.
104. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA (2010) Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 46(9): 1679-1691.
105. Liu HS, Hsu PY, Lai MD, Chang HY, Ho CL, Cheng HL et al (2010) An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells. Carcinogenesis 31(8):1456-1464.
106. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC (2011) VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One 6(9):e25668.
107. Lyu J, Yamamoto V, Lu W (2008) Cleavage of the Wnt receptor Ryk regulates neuronal differentiation during cortical neurogenesis. Dev Cell 15(5):773-780.
108. Zhong WM (2008) Going nuclear is again a winning (Wnt) strategy. Dev Cell 15(5): 635-636.
109. Zhong J, Kim HT, Lyu J, Yoshikawa K, Nakafuku M, Lu W (2011) The Wnt receptor Ryk controls specification of GABAergic neurons versus oligodendrocytes during telencephalon development. Development 138(3):409-419.
110. Tseng HC, Lyu PC, Lin WC (2010) Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain. BMC Cell Biol 11:48.
111. Tseng HC, Kao HW, Ho MR, Chen YR, Lin TW, Lyu PC et al (2011) Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. Anticancer Res 31(12):4239-4249.
112. Yankner BA, Shooter EM (1979) Nerve growth factor in the nucleus: interaction with receptors on the nuclear membrane. Proc Natl Acad Sci USA 76(3):1269-1273.
113. Zhang Z, Yang Y, Gong A, Wang C, Liang Y, Chen Y (2005) Localization of NGF and TrkA at mitotic apparatus in human glioma cell line U251. Biochem Biophys Res Commun 337(1):68-74.
114. Thakur MK, Paramanik V (2012) Expression of Trk a and Src and their interaction with ERbeta ligand binding domain show age and sex dependent alteration in mouse brain. Neurochem Res 37(2):448-453.
115. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC et al (2006) Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 8(12):1359-1368.
116. Maga G, Hubscher U (2003) Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 116(Pt 15):3051-3060.
117. Moldovan GL, Pfander B, Jentsch S (2007) PCNA, the maestro of the replication fork. Cell 129(4):665-679.
118. Psyrri A, Egleston B, Weinberger P, Yu Z, Kowalski D, Sasaki C et al (2008) Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev 17(6):1486-1492.
119. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L et al (2005) Radiationinduced epidermal growth factor receptor nuclear import is linked to activation of DNAdependent protein kinase. J Biol Chem 280(35):31182-31189.
120. Wanner G, Mayer C, Kehlbach R, Rodemann HP, Dittmann K (2008) Activation of protein kinase cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol 86(3):383-390.
121. Javvadi P, Makino H, Das AK, Lin YF, Chen DJ, Chen BP et al (2012) Threonine 2609 phosphorylation of the DNA-dependent protein Kinase is a critical prerequisite for epidermal growth factor receptor mediated radiation resistance. Mol Cancer Res 10(10):1359-1368.
122. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Kehlbach R, Rodemann HP (2011) Nuclear epidermal growth factor receptor modulates cellular radio-sensitivity by regulation of chromatin access. Radiother Oncol 99(3):317-322.
123. Das AK, Chen BP, Story MD, Sato M, Minna JD, Chen DJ et al (2007) Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFRmediated radioprotection in non-small cell lung carcinoma. Cancer Res 67(11):5267-5274.
124. Liccardi G, Hartley JA, Hochhauser D (2011) EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 71(3):1103-1114.
125. Hsu SC, Miller SA, Wang Y, Hung MC (2009) Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res 1(3):249-258.
126. Lee PC, Lee HJ, Kakadiya R, Sanjiv K, Su TL, Lee TC (2012) Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity. Oncogene 32(9):1144-1154.
127. Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol 76(2):157-161.
128. Xu Y, Shao Y, Zhou J, Voorhees JJ, Fisher GJ (2009) Ultraviolet irradiation-induces epidermal growth factor receptor (EGFR) nuclear translocation in human keratinocytes. J Cell Biochem 107(5):873-880.
129. Chen DJ, Nirodi CS (2007) The epidermal growth factor receptor: a role in repair of radiationinduced DNA damage. Clin Cancer Res 13(22 Pt 1):6555-6560.
130. Szumiel I (2006) Epidermal growth factor receptor and DNA double strand break repair: the cell's self-defence. Cell Signal 18(10):1537-1548.
131. Umar A, Buermeyer AB, Simon JA, Thomas DC, Clark AB, Liskay RM et al (1996) Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell 87(1):65-73.
132. Luo B, Yu S, Zhuang L, Xia S, Zhao Z, Rong L (2009) Induction of ERBB2 nuclear transport after radiation in breast cancer cells. J Huazhong Univ Sci Technol Med Sci 29(3):350-353.
133. Boone JJ, Bhosle J, Tilby MJ, Hartley JA, Hochhauser D (2009) Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 8(11):3015-3023.
134. Icli B, Bharti A, Pentassuglia L, Peng X, Sawyer DB (2012) ErbB4 Localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response. Biochem Biophys Res Commun 418(1):116-121.
135. Robertson DM, Zhu M, Wu YC (2012) Cellular distribution of the IGF-1R in corneal epithelial cells. Exp Eye Res 94(1):179-186.
136. Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RM, DeRyckere D et al (2012) Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One 7(2):e31635.
137. Seol KC, Kim SJ (2003) Nuclear matrix association of insulin receptor and IRS-1 by insulin in osteoblast-like UMR-106 cells. Biochem Biophys Res Commun 306(4):898-904.
138. Stachowiak MK, Maher PA, Joy A, Mordechai E, Stachowiak EK (1996) Nuclear localization of functional FGF receptor 1 in human astrocytes suggests a novel mechanism for growth factor action. Brain Res Mol Brain Res 38(1):161-165.
139. Bueter W, Dammann O, Zscheppang K, Korenbaum E, Dammann CE (2006) ErbB receptors in fetal endothelium - a potential linkage point for inflammation-associated neonatal disorders. Cytokine 36(5-6):267-275.
140. Li LY, Chen H, Hsieh YH, Wang YN, Chu HJ, Chen YH et al (2011) Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes. Cancer Res 71(12):4269-4279.
141. Thompson M, Lauderdale S, Webster MJ, Chong VZ, McClintock B, Saunders R et al (2007) Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. Brain Res 1139:95-109.
142. Hernandez-Verdun D, Roussel P, Thiry M, Sirri V, Lafontaine DL (2010) The nucleolus: structure/function relationship in RNA metabolism. Wiley Interdiscip Rev RNA 1(3): 415-431.
143. Mao YS, Zhang B, Spector DL (2011) Biogenesis and function of nuclear bodies. Trends Genet 27(8):295-306.
144. Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW (2002) c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 157 (6): 929-939.
145. Rodrigues MA, Gomes DA, Andrade VA, Leite MF, Nathanson MH (2008) Insulin induces calcium signals in the nucleus of rat hepatocytes. Hepatology 48(5):1621-1631.
146. Gomes DA, Rodrigues MA, Leite MF, Gomez MV, Varnai P, Balla T et al (2008) c-Met must translocate to the nucleus to initiate calcium signals. J Biol Chem 283(7):4344-4351.
147. Hardingham GE, Chawla S, Johnson CM, Bading H (1997) Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 385(6613):260-265.
148. Rodrigues MA, Gomes DA, Leite MF, Grant W, Zhang L, Lam W et al (2007) Nucleoplasmic calcium is required for cell proliferation. J Biol Chem 282(23):17061-17068.
149. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P (2004) Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 50(1):23-38.
150. Fischer OM, Gschwind A, Ullrich AA (2004) Cell surface growth factor receptor molecules as targets for cancer therapy. Discov Med 4(22):166-171.
151. Takeuchi K, Ito F (2011) Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 34(12):1774-1780.
152. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15-31.
153. Rosenzweig SA (2012) Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 83(8):1041-1048.
154. Patel R, Leung HY (2012) Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des 18(19):2672-2679.
155. Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77(6):400-410.
156. Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F (2005) Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. J Cell Physiol 205(3):355-363.
157. Normanno N, De Luca A, Maiello MR, Mancino M, D'Antonio A, Macaluso M et al (2005) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. Front Biosci 10:2611-2617.
158. Redmond KM, Wilson TR, Johnston PG, Longley DB (2008) Resistance mechanisms to cancer chemotherapy. Front Biosci 13:5138-5154.
159. Giaccone G, Wang Y (2011) Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 37(6):456-464.
160. Dittmann K, Mayer C, Kehlbach R, Rodemann HP (2008) The radioprotector Bowman-Birk proteinase inhibitor stimulates DNA repair via epidermal growth factor receptor phosphorylation and nuclear transport. Radiother Oncol 86(3):375-382.
161. Yu YL, Chou RH, Wu CH, Wang YN, Chang WJ, Tseng YJ et al (2012) Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776. J Biol Chem 287(37):31015-31026.
162. Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY et al (2011) Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One 6(6):e21428.
163. Liao HJ, Carpenter G (2009) Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res 69(15):6179-6183.
164. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28(43):3801-3813.
165. Ryu SH, Lee SW, Yang YJ, Song SY, Kim JH, Choi EK et al (2012) Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines. Lung Cancer 77(3):482-487.
166. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S et al (2002) Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxolinduced apoptosis. Mol Cell 9(5):993-1004.
167. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99(8):628-638.
168. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J et al (2006) Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25(13):3234-3244.
169. Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS et al (2011) Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther 10(8):1367-1374.
170. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al (2010) A chromatin- mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1):69-80.
171. Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C (2012) Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol 227(7):2947-2952.
172. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17(3):313-319.
173. Yu Y, Ramena G, Elble RC (2012) The role of cancer stem cells in relapse of solid tumors. Front Biosci 4:1528-1541
174. Stachowiak MK, Maher PA, Stachowiak EK (2007) Integrative nuclear signaling in cell development-a role for FGF receptor-1. DNA Cell Biol 26(12):811-826.
175. Wang YN, Lee HH, Lee HJ, Du Y, Yamaguchi H, Hung MC (2012) Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. J Biol Chem 287(20):16869-16879.
176. Du Y, Shen J, Hsu J, Han Z, Hsu M, Yang C et al (2013) Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking. Oncogene. In press
177. Dittmann K, Mayer C, Kehlbach R, Rodemann HP (2008) Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 7:69.
178. Dittmann K, Mayer C, Kehlbach R, Rothmund MC, Rodemann Peter H (2009) Radiationinduced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol 92(3):379-382.
179. Iida M, Brand TM, Campbell DA, Li C, Wheeler DL (2013) Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 32(6):759-767.
180. Li C, Iida M, Dunn EF, Wheeler DL (2010) Dasatinib blocks cetuximab- and radiationinduced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 97(2):330-337.
181. Nowsheen S, Bonner JA, Yang ES (2011) The poly(ADP-ribose) polymerase inhibitor ABT- 888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 99(3):331-338.
182. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd et al (2007) Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 67(15):7319-7326.
183. Conway-Campbell BL, Brooks AJ, Robinson PJ, Perani M, Waters MJ (2008) The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation. Mol Endocrinol 22(9):2190-2202.
184. Chiu HC, Chang TY, Huang CT, Chao YS, Hsu JT (2012) EGFR and myosin II inhibitors cooperate to suppress EGFR-T790M-mutant NSCLC cells. Mol Oncol 6(3):299-310.
185. Reilly RM, Kiarash R, Cameron RG, Porlier N, Sandhu J, Hill RP et al (2000) 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 41(3): 429-438.
186. Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA (2008) Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med 49(8):1353-1361.
187. Hu M, Scollard D, Chan C, Chen P, Vallis K, Reilly RM (2007) Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normaltissue uptake of [111In]DTPA-hEGF. Nucl Med Biol 34(8):887-896.
188. Chen P, Cameron R, Wang J, Vallis KA, Reilly RM (2003) Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 44(9):1469-1478.
189. Bailey KE, Costantini DL, Cai Z, Scollard DA, Chen Z, Reilly RM et al (2007) Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. J Nucl Med 48(9):1562-1570.
190. Cornelissen B, Darbar S, Hernandez R, Kersemans V, Tullis I, Barber PR et al (2011) ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)in-DTPA-hEGF auger electron radiation therapy. J Nucl Med 52(5):776-783.
191. Reilly RM, Chen P, Wang J, Scollard D, Cameron R, Vallis KA (2006) Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med 47(6):1023-1031.
192. Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ et al (2012) In-Bn-DTPAnimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (herceptin)-resistant breast cancer. Breast Cancer Res Treat 135(1):189-200(1)(1)(1)
193. Hung MC, Link W (2011) Protein localization in disease and therapy. J Cell Sci 124 (Pt 20):3381-3392.
194. De Angelis Campos AC, Rodrigues MA, de Andrade C, de Goes AM, Nathanson MH, Gomes DA (2011) Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway. Biochem Biophys Res Commun 412(2):341-346.
195. Li A, Zhang C, Gao S, Chen F, Yang C, Luo R et al (2013) TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice. Oncogene 32(18):2273-2281.
196. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ et al (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22(4):449-462.
197. Marti U, Ruchti C, Kampf J, Thomas GA, Williams ED, Peter HJ et al (2001) Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 11(2):137-145.
198. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB et al (2009) Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res 15(6):2098-2106.
199. Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F (2011) Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol 225(4):565-573.
200. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R et al (2004) Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101(29):10715-10720.
201. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S et al (2011) HER2/ErbB2 Receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol 25(1):92-103.
202. Raabe TD, Deadwyler G, Varga JW, Devries GH (2004) Localization of neuregulin isoforms and erbB receptors in myelinating glial cells. Glia 45(2):197-207.
203. Koumakpayi IH, Le Page C, Delvoye N, Saad F, Mes-Masson AM (2011) Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Mol Carcinog 50(11):901-912.
204. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE (2008) The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68(15):6387-6395.
205. Thor AD, Edgerton SM, Jones FE (2009) Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol 175(5):1802-1809.
206. Hu Y, Fang X, Dunham SM, Prada C, Stachowiak EK, Stachowiak MK (2004) 90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling. J Biol Chem 279(28): 29325-29335.
207. Dunham-Ems SM, Lee YW, Stachowiak EK, Pudavar H, Claus P, Prasad PN et al (2009) Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. Mol Biol Cell 20(9):2401-2412.
208. Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA et al (2008) Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: a role for the FGF-2/FGFR-2 axis. Int J Cancer 123(11):2518-2531.
209. Cerliani JP, Vanzulli SI, Pinero CP, Bottino MC, Sahores A, Nunez M et al (2012) Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. Breast Cancer Res Treat 133(3):997-1008.
210. Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J et al (2011) FGFR2 Alterations in endometrial carcinoma. Mod Pathol 24(11):1500-1510.
211. Martin AJ, Grant A, Ashfield AM, Palmer CN, Baker L, Quinlan PR et al (2011) FGFR2 Protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes 4:72.
212. Lu P, Ewald AJ, Martin GR, Werb Z (2008) Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 321(1):77-87.
213. Nyeng P, Norgaard GA, Kobberup S, Jensen J (2007) FGF10 Signaling controls stomach morphogenesis. Dev Biol 303(1):295-310.
214. Sabbieti MG, Marchetti L, Gabrielli MG, Menghi M, Materazzi S, Menghi G et al (2005) Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase. Cell Tissue Res 319(2):267-278.
215. Schmahl J, Kim Y, Colvin JS, Ornitz DM, Capel B (2004) Fgf9 Induces proliferation and nuclear localization of FGFR2 in sertoli precursors during male sex determination. Development 131(15):3627-3636.
216. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN et al (2005) Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 92(2):320-327.
217. Kuroso K, Imai Y, Kobayashi M, Yanagimoto K, Suzuki T, Kojima M et al (2010) Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology 77(5):231-240.
218. Zammit C, Barnard R, Gomm J, Coope R, Shousha S, Coombes C et al (2001) Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol 194(1):27-34.
219. Reid S, Ferretti P (2003) Differential expression of fibroblast growth factor receptors in the developing murine choroid plexus. Brain Res Dev Brain Res 141(1-2):15-24.
220. Kiunga GA, Raju J, Sabljic N, Bajaj G, Good CK, Bird RP (2004) Elevated insulin receptor protein expression in experimentally induced colonic tumors. Cancer Lett 211(2):145-153.
221. Mattarocci S, Abbruzzese C, Mileo AM, Visca P, Antoniani B, Alessandrini G et al (2009) Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer. J Cell Physiol 221(3):766-770.
222. Gletsu NA, Field CJ, Clandinin MT (1999) Obese mice have higher insulin receptor levels in the hepatocyte cell nucleus following insulin stimulation in vivo with an oral glucose meal. Biochim Biophys Acta 1454(3):251-260.
223. Podlecki DA, Smith RM, Kao M, Tsai P, Huecksteadt T, Brandenburg D et al (1987) Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects. J Biol Chem 262(7):3362-3368.
224. Kim SJ, Kahn CR (1993) Insulin induces rapid accumulation of insulin receptors and increases tyrosine kinase activity in the nucleus of cultured adipocytes. J Cell Physiol 157(2):217-228.
225. Hoa N, Tsui S, Afifiyan NF, Sinha Hikim A, Li B, Douglas RS et al (2012) Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17. PLoS One 7(4):e34173.
226. Blazquez C, Cook N, Micklem K, Harris AL, Gatter KC, Pezzella F (2006) Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Res 16(1):93-98.
227. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M (2004) Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64(16):5617-5623.
228. Mylona E, Alexandrou P, Mpakali A, Giannopoulou I, Liapis G, Markaki S et al (2007) Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol 33(3):294-300.
229. Santos SC, Dias S (2004) Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103(10):3883-3889.
230. Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D et al (2003) The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 43(1):33-39.
231. Andersson MK, Goransson M, Olofsson A, Andersson C, Aman P (2010) Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop. BMC Cancer 10:249.
232. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE (2010) VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 17(3):499-512.
233. Dardik R, Inbal A (2006) Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 312(16):2973-2982.
234. Feng Y, Venema VJ, Venema RC, Tsai N, Caldwell RB (1999) VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem Biophys Res Commun 256(1):192-197.
235. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y et al (2007) VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res 313(8):1561-1574.
236. Susarla R, Gonzalez AM, Watkinson JC, Eggo MC (2012) Expression of receptors for VEGFs on normal human thyroid follicular cells and their role in follicle formation. J Cell Physiol 227(5):1992-2002.
237. Thuringer D, Maulon L, Frelin C (2002) Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 277(3):2028-2032.
238. Hagedorn A, Germann PG, Junker-Walker U, Tomovic A, Seewald W, Polkinghorne A et al (2005) Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey. Exp Toxicol Pathol 57(2):149-159.
239. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65(4):1479-1488.
240. Pozner-Moulis S, Pappas DJ, Rimm DL (2006) Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res 66(16):7976-7982.
241. Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH (2010) MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci 51(7):3333-3339.
242. Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B et al (2008) Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci 49(2):497-504.
243. Saitoh K, Takahashi H, Sawada N, Parsons PG (1994) Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin. J Pathol 174(3):191-199.
244. Moughal NA, Waters C, Sambi B, Pyne S, Pyne NJ (2004) Nerve growth factor signaling involves interaction between the Trk a receptor and lysophosphatidate receptor 1 systems: nuclear translocation of the lysophosphatidate receptor 1 and Trk a receptors in pheochromocytoma 12 cells. Cell Signal 16(1):127-136.
245. Gong A, Zhang Z, Xiao D, Yang Y, Wang Y, Chen Y (2007) Localization of phosphorylated TrkA in carrier vesicles involved in its nuclear translocation in U251 cell line. Sci China C Life Sci 50(2):141-146.
246. Mufson EJ, Presley LN, Kordower JH (1991) Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and colocalization with cholinergic neurons. Brain Res 539(1):19-30.
247. Bonacchi A, Taddei ML, Petrai I, Efsen E, Defranco R, Nosi D et al (2008) Nuclear localization of TRK-a in liver cells. Histol Histopathol 23(3):327-340.
248. Munoz M, Rodriguez A, Diez C, Caamano JN, Fernandez-Sanchez MT, Perez-Gomez A et al (2009) Tyrosine kinase a, C and fibroblast growth factor-2 receptors in bovine embryos cultured in vitro. Theriogenology 71(6):1005-1010.
249. Marti U, Wells A (2000) The nuclear accumulation of a variant epidermal growth factor receptor (EGFR) lacking the transmembrane domain requires coexpression of a full-length EGFR. Mol Cell Biol Res Commun 3(1):8-14.
250. Castillo M, Petit A, Mellado B, Palacin A, Alcover JB, Mallofre C (2004) C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with Imatinib. J Urol 171(6 Pt 1):2176-2180.
251. Hong SM, Hwang I, Song DE, Choi J, Yu E (2007) Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. Mod Pathol 20(5):562-569.
252. Di Matteo G, Pescarmona E, Peparini N, Di Matteo FM, Zeri KP, Mascagni D et al (2002) Histopathological features and clinical course of the gastrointestinal stromal tumors. Hepatogastroenterology 49(46):1013-1016.
253. Liao HJ, Carpenter G (2012) Regulated intramembrane cleavage of the EGF receptor. Traffic 13(8):1106-1112.
254. Degnin CR, Laederich MB, Horton WA (2011) Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3. Mol Biol Cell 22(20):3861-3873.
255. Cai J, Jiang WG, Grant MB, Boulton M (2006) Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281(6):3604-3613.
256. Wu LW (ed) (2010) Evidence and actions for nuclear localization of vascular endothelial growth factor 1 (VEGFR1) in endothelial and cancer cells. Proceedings of the 101st annual meeting of the American Association for Cancer Research, April 2010. AACR, Washington, DC, Philadelphia, pp 17-21